By Editor • August 27, 2026 • 1 min read
Merck and Moderna's personalized cancer vaccine may be the first to use an algorithm for its genetic design, but skepticism remains about its necessity.
Read moreBy Editor • August 27, 2026 • 1 min read
Moderna's personalized cancer vaccine may become the first approved treatment with mRNA instructions generated by AI, following a successful trial with Merck.
Read moreBy Editor • August 24, 2026 • 1 min read
Moderna and Merck's cancer vaccine shows early promise in reducing melanoma recurrence, but skepticism remains among experts and investors.
Read moreBy Editor • August 20, 2026 • 1 min read
Merck and Moderna's mRNA cancer therapy success marks 2026 as a pivotal year in cancer treatment advancements.
Read moreBy Editor • August 19, 2026 • 1 min read
Merck and Moderna's personalized mRNA therapy intismeran autogene achieves a milestone in melanoma treatment with positive phase 3 trial results.
Read moreBy Editor • August 19, 2026 • 1 min read
Merck and Moderna report success in a late-stage trial for their personalized mRNA cancer vaccine, signaling a breakthrough in cancer treatment.
Read moreBy Editor • August 19, 2026 • 1 min read
Moderna and Merck's mRNA cancer vaccine shows promise in a Phase 3 trial for melanoma, highlighting advancements in personalized cancer treatment.
Read moreBy Editor • August 19, 2026 • 1 min read
Merck and Moderna report promising trial results for their melanoma vaccine, intismeran autogene, in combination with Keytruda.
Read more
